Ticagrelor Enhances Release of Anti-Hypoxic Cardiac Progenitor Cell-Derived Exosomes Through Increasing Cell Proliferation In Vitro.
Aged
Animals
Apoptosis
Aurora Kinases
/ metabolism
Cell Hypoxia
Cell Proliferation
Cells, Cultured
Exosomes
/ drug effects
HSP70 Heat-Shock Proteins
/ metabolism
Humans
MAP Kinase Signaling System
Mice
Myocytes, Cardiac
/ drug effects
Purinergic P2Y Receptor Antagonists
/ pharmacology
Ticagrelor
/ pharmacology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 02 2020
12 02 2020
Historique:
received:
02
09
2019
accepted:
27
01
2020
entrez:
14
2
2020
pubmed:
14
2
2020
medline:
18
11
2020
Statut:
epublish
Résumé
Despite the widespread clinical use of cardioprotection by long-term direct antagonism of P2Y12 receptor, underlying mechanisms are unclear. Here, we identify how release of pro-survival exosomes from human cardiac-derived mesenchymal progenitor cells (hCPCs) is regulated by clinically relevant dose of ticagrelor (1 μM), an oral selective and reversible non-thienopyridine P2Y
Identifiants
pubmed: 32051439
doi: 10.1038/s41598-020-59225-7
pii: 10.1038/s41598-020-59225-7
pmc: PMC7016113
doi:
Substances chimiques
HSP70 Heat-Shock Proteins
0
Purinergic P2Y Receptor Antagonists
0
Aurora Kinases
EC 2.7.11.1
Ticagrelor
GLH0314RVC
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2494Références
Reed, G. W., Rossi, J. E. & Cannon, C. P. Acute myocardial infarction. Lancet 389, 197–210 (2017).
pubmed: 27502078
doi: 10.1016/S0140-6736(16)30677-8
pmcid: 27502078
Araszkiewicz, A. et al. Effect of impaired myocardial reperfusion on left ventricular remodeling in patients with anterior wall acute myocardial infarction treated with primary coronary intervention. Am. J. Cardiol. 98, 725–728 (2006).
pubmed: 16950171
doi: 10.1016/j.amjcard.2006.04.009
pmcid: 16950171
Lionetti, V., Bianchi, G., Recchia, F. A. & Ventura, C. Control of autocrine and paracrine myocardial signals: an emerging therapeutic strategy in heart failure. Heart Fail. Rev. 15, 531–542 (2010).
pubmed: 20364318
doi: 10.1007/s10741-010-9165-7
pmcid: 20364318
Vilahur, G. et al. Protective Effects of Ticagrelor on Myocardial Injury After Infarction. Circulation 134, 1708–1719 (2016).
pubmed: 27789556
doi: 10.1161/CIRCULATIONAHA.116.024014
pmcid: 27789556
Vilahur, G. et al. P2Y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs. Cardiovasc. Res. 114, 1860–1870 (2018).
pubmed: 30124783
doi: 10.1093/cvr/cvy201
pmcid: 30124783
Audia, J. P. et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. Basic Res. Cardiol. 113, 32 (2018).
pubmed: 29992382
pmcid: 6396295
doi: 10.1007/s00395-018-0692-z
Ye, Y. et al. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 35, 1805–1814 (2015).
pubmed: 26044583
doi: 10.1161/ATVBAHA.115.305655
pmcid: 26044583
Nanhwan, M. K. et al. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler. Thromb. Vasc. Biol. 34, 2078–2085 (2014).
pubmed: 25012137
doi: 10.1161/ATVBAHA.114.304002
pmcid: 25012137
Bansilal, S. et al. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. J. Am. Coll. Cardiol. 71, 489–496 (2018).
pubmed: 29406853
doi: 10.1016/j.jacc.2017.11.050
pmcid: 29406853
Khan, J.N. et al. Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study. J. Am. Heart Assoc. 5, https://doi.org/10.1161/JAHA.116.003403 (2016).
Bonaca, M. P. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372, 1791–800 (2015).
pubmed: 25773268
doi: 10.1056/NEJMoa1500857
pmcid: 25773268
Roubille, F. et al. Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis. Basic Res. Cardiol. 107, 275 (2012).
pubmed: 22718009
doi: 10.1007/s00395-012-0275-3
pmcid: 22718009
Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045–1057 (2009).
pubmed: 19717846
doi: 10.1056/NEJMoa0904327
pmcid: 19717846
Cannon, C. P. et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 375, 283–293 (2010).
pubmed: 20079528
doi: 10.1016/S0140-6736(09)62191-7
pmcid: 20079528
Findik, O. et al. Ticagrelor Attenuates Apoptosis of Lung and Myocardial Cells Induced by Abdominal Aorta Ischemia/Reperfusion. In Vivo 30, 243–249 (2016).
pubmed: 27107082
pmcid: 27107082
Cattaneo, M., Schulz, R. & Nylander, S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J. Am. Coll. Cardiol. 63, 2503–2509 (2014).
pubmed: 24768873
doi: 10.1016/j.jacc.2014.03.031
pmcid: 24768873
van den Berg, T. N. et al. Ticagrelor Does Not Inhibit Adenosine Transport at Relevant Concentrations: A Randomized Cross-Over Study in Healthy Subjects In Vivo. PLoS One 10, e0137560, https://doi.org/10.1371/journal.pone.0137560 (2015).
doi: 10.1371/journal.pone.0137560
pubmed: 26509673
pmcid: 4624811
Löfgren, L., Pehrsson, S., Hägglund, G., Tjellström, H. & Nylander, S. Accurate measurement of endogenous adenosine in human blood. PLoS One 13, e0205707, https://doi.org/10.1371/journal.pone.0205707 (2018).
doi: 10.1371/journal.pone.0205707
pubmed: 30359421
pmcid: 6201894
Yang, X. M. et al. Ticagrelor Does Not Protect Isolated Rat Hearts, Thus Clouding Its Proposed Cardioprotective Role Through ENT 1 in Heart Tissue. J. Cardiovasc. Pharmacol. Ther. 24, 371–376 (2019).
pubmed: 30744423
doi: 10.1177/1074248419829169
pmcid: 30744423
Mauretti, A., Spaans, S., Bax, N. A. M., Sahlgren, C. & Bouten, C. V. C. Cardiac Progenitor Cells and the Interplay with Their Microenvironment. Stem Cells Int. 2017, 7471582, https://doi.org/10.1155/2017/7471582 (2017).
doi: 10.1155/2017/7471582
pubmed: 29075298
pmcid: 5623801
Barile, L. et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc. Res. 103, 530–541 (2014).
pubmed: 25016614
doi: 10.1093/cvr/cvu167
pmcid: 25016614
Ibrahim, A. G., Cheng, K. & Marbán, E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports 2, 606–619 (2014).
pubmed: 24936449
pmcid: 4050492
doi: 10.1016/j.stemcr.2014.04.006
Barile, L. et al. Cardioprotection by cardiac progenitor cell-secreted exosomes: role of pregnancy-associated plasma protein-A. Cardiovasc. Res. 114, 992–1005 (2018).
pubmed: 29518183
doi: 10.1093/cvr/cvy055
pmcid: 29518183
Gray, W. D. et al. Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. Circ. Res. 116, 255–263 (2015).
pubmed: 25344555
doi: 10.1161/CIRCRESAHA.116.304360
pmcid: 25344555
Gasecka, A. et al. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets: Preliminary results. Cardiol. J. (In press) 19 Apr 2018.
Saha, P. et al. Circulating exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic myocardium. Sci. Transl. Med. 11, https://doi.org/10.1126/scitranslmed.aau1168 (2019).
pubmed: 31118291
doi: 10.1126/scitranslmed.aau1168
pmcid: 31118291
Wang, L., Jacobsen, S. E., Bengtsson, A. & Erlinge, D. P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol. 5, 16 (2004).
pubmed: 15291969
pmcid: 509419
doi: 10.1186/1471-2172-5-16
Xiong, H. et al. Up-regulation of miR-138 inhibits hypoxia-induced cardiomyocyte apoptosis via down-regulating lipocalin-2 expression. Exp. Biol. Med. (Maywood) 241, 25–30 (2016).
doi: 10.1177/1535370215591831
Théry, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7, 1535750, https://doi.org/10.1080/20013078.2018.1535750 (2018).
doi: 10.1080/20013078.2018.1535750
pubmed: 30637094
pmcid: 6322352
Nylander, S. et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J. Thromb. Haemost. 11, 1867–1876 (2013).
pubmed: 23890048
pmcid: 23890048
Barile, L., Moccetti, T., Marbán, E. & Vassalli, G. Roles of exosomes in cardioprotection. Eur. Heart J. 38, 1372–1379 (2017).
pubmed: 27443883
pmcid: 27443883
Savina, A., Furlán, M., Vidal, M. & Colombo, M. I. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J. Biol. Chem. 278, 20083–20090 (2003).
pubmed: 12639953
doi: 10.1074/jbc.M301642200
pmcid: 12639953
Verweij, F. J. et al. Quantifying exosome secretion from single cells reveals a modulatory role for GPCR signaling. J. Cell. Biol. 217, 1129–1142 (2018).
pubmed: 29339438
pmcid: 5839777
doi: 10.1083/jcb.201703206
Aungraheeta, R. et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood 128, 2717–2728 (2016).
pubmed: 27694321
pmcid: 5161012
doi: 10.1182/blood-2016-03-707844
Patel, D. B. et al. Impact of cell culture parameters on production and vascularization bioactivity of mesenchymal stem cell-derived extracellular vesicles. Bioeng. Transl. Med. 2, 170–179 (2017).
pubmed: 28932818
pmcid: 5579732
doi: 10.1002/btm2.10065
Oh, H. et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc. Natl. Acad. Sci. USA 100, 12313–12318 (2003).
pubmed: 14530411
doi: 10.1073/pnas.2132126100
pmcid: 14530411
Bonello, L. et al. Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective randomized study. Int. J. Cardiol. 187, 502–507 (2015).
pubmed: 25846661
doi: 10.1016/j.ijcard.2015.03.414
pmcid: 25846661
Zhang, M. et al. Exosomal 15-LO2 mediates hypoxia-induced pulmonary artery hypertension in vivo and in vitro. Cell Death Dis. 9, 1022 (2018).
pubmed: 30282973
pmcid: 6170379
doi: 10.1038/s41419-018-1073-0
Helenius, M., Jalkanen, S. & Yegutkin, G. Enzyme-coupled assays for simultaneous detection of nanomolar ATP, ADP, AMP, adenosine, inosine and pyrophosphate concentrations in extracellular fluids. Biochim. Biophys. Acta 1823, 1967–1975 (2012).
pubmed: 22967714
doi: 10.1016/j.bbamcr.2012.08.001
pmcid: 22967714
Ohman, J., Kudira, R., Albinsson, S., Olde, B. & Erlinge, D. Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem. Biophys. Res. Commun. 418, 754–758 (2012).
pubmed: 22306816
doi: 10.1016/j.bbrc.2012.01.093
pmcid: 22306816
Armstrong, D. et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J. Cardiovasc. Pharmacol. Ther. 19, 209–219 (2014).
pubmed: 24414167
doi: 10.1177/1074248413511693
pmcid: 24414167
Ezura, Y., Lin, X., Hatta, A., Izu, Y. & Noda, M. Interleukin-1β Suppresses the Transporter Genes Ank and Ent1 Expression in Stromal Progenitor Cells Retaining Mineralization. Calcif. Tissue Int. 99, 199–208 (2016).
pubmed: 27086348
doi: 10.1007/s00223-016-0139-1
pmcid: 27086348
Guzmán-Gutiérrez, E. et al. Differential expression of functional nucleoside transporters in non-differentiated and differentiated human endothelial progenitor cells. Placenta 31, 928–936 (2010).
pubmed: 20728214
doi: 10.1016/j.placenta.2010.07.016
pmcid: 20728214
Lv, J., Shao, Y. & Gao, Y. Activation of A1 and A2a adenosine receptors promotes neural progenitor cell proliferation. Brain Res. 1686, 65–71 (2018).
pubmed: 29476752
doi: 10.1016/j.brainres.2018.02.028
pmcid: 29476752
Carroll, S. H. et al. A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. J. Biol. Chem. 287, 15718–15727 (2012).
pubmed: 22403399
pmcid: 3346096
doi: 10.1074/jbc.M112.344994
Ryzhov, S. et al. Role of adenosine A2B receptor signaling in contribution of cardiac mesenchymal stem-like cells to myocardial scar formation. Purinergic Signal. 10, 477–486 (2014).
pubmed: 24584483
pmcid: 4152448
doi: 10.1007/s11302-014-9410-y
Pragnacharyulu, P. V., Varkhedkar, V., Curtis, M. A., Chang, I. F. & Abushanab, E. Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2′S-hydroxy-3′R-nonyl)adenine [(+)-EHNA]. J. Med. Chem. 43, 4694–4700 (2000).
pubmed: 11101360
doi: 10.1021/jm0002533
pmcid: 11101360
Ahmad, A., Schaack, J. B., White, C. W. & Ahmad, S. Adenosine A2A receptor-dependent proliferation of pulmonary endothelial cells is mediated through calcium mobilization, PI3-kinase and ERK1/2 pathways. Biochem. Biophys. Res. Commun. 434, 566–571 (2013).
pubmed: 23583199
pmcid: 4046330
doi: 10.1016/j.bbrc.2013.03.115
Drobic, B., Pérez-Cadahía, B., Yu, J., Kung, S. K. & Davie, J. R. Promoter chromatin remodeling of immediate-early genes is mediated through H3 phosphorylation at either serine 28 or 10 by the MSK1 multi-protein complex. Nucleic Acids Res. 38, 3196–3208 (2010).
pubmed: 20129940
pmcid: 2879512
doi: 10.1093/nar/gkq030
Agarwal, K. et al. Analysis of exosome release as a cellular response to MAPK pathway inhibition. Langmuir 31, 5440–5448 (2015).
pubmed: 25915504
pmcid: 4589192
doi: 10.1021/acs.langmuir.5b00095
Arbitrario, J. P. et al. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother. Pharmacol. 65, 707–717 (2010).
pubmed: 19649632
doi: 10.1007/s00280-009-1076-8
pmcid: 19649632
Rose, J. B. et al. Equilibrative nucleoside transporter 1 plays an essential role in cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 298, H771–777 (2010).
pubmed: 20035027
doi: 10.1152/ajpheart.00711.2009
pmcid: 20035027
Kacimi, R., Chentoufi, J., Honbo, N., Long, C. S. & Karliner, J. S. Hypoxia differentially regulates stress proteins in cultured cardiomyocytes: role of the p38 stress-activated kinase signaling cascade, and relation to cytoprotection. Cardiovasc. Res. 46, 139–150 (2000).
pubmed: 10727662
doi: 10.1016/S0008-6363(00)00007-9
pmcid: 10727662
Huang, P. et al. Atorvastatin Enhances the Therapeutic Efficacy of Mesenchymal Stem Cells Derived Exosomes in Acute Myocardial Infarction via Up-regulating Long Non-coding RNA H19. Cardiovasc. Res. 2019 May 22. pii: cvz139 (In Press).
Chang, W. et al. Mesenchymal stem cells pretreated with delivered Hph-1-Hsp70 protein are protected from hypoxia-mediated cell death and rescue heart functions from myocardial injury. Stem Cells 27, 2283–2292 (2009).
pubmed: 19544472
doi: 10.1002/stem.153
pmcid: 19544472
Vicencio, J. M. et al. Plasma exosomes protect the myocardium from ischemia-reperfusion injury. J. Am. Coll. Cardiol. 65, 1525–1536 (2015).
pubmed: 25881934
doi: 10.1016/j.jacc.2015.02.026
pmcid: 25881934
Davidson, S. M. et al. Cardioprotection mediated by exosomes is impaired in the setting of type II diabetes but can be rescued by the use of non-diabetic exosomes in vitro. J. Cell. Mol. Med. 22, 141–151 (2018).
pubmed: 28840975
doi: 10.1111/jcmm.13302
pmcid: 28840975
Yu, B., Meng, F., Yang, Y., Liu, D. & Shi, K. NOX2 Antisense Attenuates Hypoxia-Induced Oxidative Stress and Apoptosis in Cardiomyocyte. Int. J. Med. Sci. 13, 646–652 (2016).
pubmed: 27499697
pmcid: 4974913
doi: 10.7150/ijms.15177
Luo, W. et al. Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1alpha but Not HIF-2alpha. J. Biol. Chem. 285, 3651–3663 (2010).
pubmed: 19940151
doi: 10.1074/jbc.M109.068577
pmcid: 19940151
Headrick, J. P. & Lasley, R. D. Adenosine receptors and reperfusion injury of the heart. Handb. Exp. Pharmacol. 193, 189–214 (2009).
doi: 10.1007/978-3-540-89615-9_7
Floyd, J. S. et al. A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin. Pharmacol. Ther. 91, 896–904 (2012).
pubmed: 22419147
doi: 10.1038/clpt.2011.295
pmcid: 22419147
White, S. M., Constantin, P. E. & Claycomb, W. C. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am. J. Physiol. Heart Circ. Physiol. 286, H823–829 (2004).
pubmed: 14766671
doi: 10.1152/ajpheart.00986.2003
pmcid: 14766671
Terrasini, N. & Lionetti, V. Exosomes in Critical Illness. Crit. Care Med. 45, 1054–1060 (2017).
pubmed: 28328650
doi: 10.1097/CCM.0000000000002328
pmcid: 28328650
Louis, K. S., Siegel, A. C. & Levy, G. A. Comparison of manual versus automated trypan blue dye exclusion method for cell counting. In: Stoddart, M.J., editor. Mammalian Cell Viability: Methods and Protocols. Series Methods in Molecular Biology. Springer Protocols; New York: 7–12 (2011).
Agostini, S. et al. A new dual-promoter system for cardiomyocyte-specific conditional induction of apoptosis. Biomed Res. Int. 2013, 845816, https://doi.org/10.1155/2013/845816 (2013).
doi: 10.1155/2013/845816
pubmed: 23573514
pmcid: 3581143
Jamnicki-Abegg, M. et al. Isoflurane inhibits cardiac myocyte apoptosis during oxidative and inflammatory stress by activating Akt and enhancing Bcl-2 expression. Anesthesiology 103, 1006–1014 (2005).
pubmed: 16249675
doi: 10.1097/00000542-200511000-00015
pmcid: 16249675
Salceda, S. & Caro, J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272, 22642–22647 (1997).
pubmed: 9278421
doi: 10.1074/jbc.272.36.22642
pmcid: 9278421
Ivandic, B. T. et al. Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. Clin. Chem. 52, 383–388 (2006).
pubmed: 16423907
doi: 10.1373/clinchem.2005.059535
pmcid: 16423907